Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule of non-cash share-based compensation expense

Non-cash share-based compensation expense, consisting of expense for stock options, Restricted Share Units ("RSUs") and Employee Share Purchase Plan ("ESPP"), was classified in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three months ended March 31,
	2021		2020
Research and development expenses	$	20,058	$	6,251
Selling, general and administrative expenses	28,668		10,628
	$	48,726	$	16,879
Less: Share-based compensation expense attributable to non-controlling interests	360		—
Share-based compensation expense attributable to Biohaven Pharmaceutical Holding Company Ltd.	$	48,366	$	16,879

Schedule of stock option activity

The following table is a summary of the Company's stock option activity for the three months ended March 31, 2021:

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2020	7,545,907	$28.21
Granted	1,135,850	$83.31
Exercised	(76,072)	$35.06
Forfeited	(56,102)	$59.17
Outstanding as of March 31, 2021	8,549,583	$35.27	7.14	$	300,544
Options exercisable as of March 31, 2021	5,298,569	$25.14	6.35	$	233,353
Vested and expected to vest as of March 31, 2021	8,549,583	$35.27	7.14	$	300,544

Schedule of RSU activity

The following table is a summary of the RSU activity for the three months ended March 31, 2021:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested outstanding as of December 31, 2020	467,160	$56.00
Granted	901,350	$83.01
Forfeited	(14,322)	$75.31
Vested	(308,669)	$71.40
Unvested outstanding as of March 31, 2021	1,045,519	$74.47